

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 1093)

VOLUNTARY ANNOUNCEMENT

INCLUSION OF ANFULIKE® IN THE NATIONAL REIMBURSEMENT DRUG LIST

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that Anfulike® (“Amphotericin B Cholesteryl Sulfate Complex for Injection (50mg)”) (the “**Product**”) of the Group has been included in the category B of the National Reimbursement Drug List (2021) (“**NRDL**”). The Product was granted drug registration approval in March 2021 and is indicated for the treatment of patients with invasive fungal infections, patients where renal impairment or drug toxicity precludes the use of effective dose of amphotericin B or patients fail in prior amphotericin B deoxycholate treatment.

Amphotericin B is a type of polyene antibiotic, and is a drug with the strongest antifungal activity and broadest antimicrobial spectrum for prevention and treatment of invasive fungal infections. Comparing with amphotericin B for injection used in clinical practice in China, Anfulike® has special mechanism of intake and release which could significantly decrease nephrotoxicity and increase dosage, thus enhancing the therapeutic index. The Product can enable more patients to have chances to get treated or cured, hence having a better survival prognosis.

The Board believes that the inclusion of Anfulike® in the NRDL demonstrates the recognition of its clinical value, novelty and patients benefit. This will also improve the affordability and accessibility of the Product and provide momentum to its long-term growth.

By Order of the Board
CSPC Pharmaceutical Group Limited
Cai Dongchen
Chairman

Hong Kong, 3 December 2021

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. WANG Qingxi, Mr. CHAK Kin Man and Dr. JIANG Hao as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan and Mr. LAW Cheuk Kin Stephen as independent non-executive directors.